Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of anlotinib hydrochloride capsules in relapsed/refractory diffuse large B-cell lymphoma
CTR20202598Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jan 2021; status: terminated.
02
Drugs
anlotinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20202598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202598.